Anti-human Siglec-2/CD22 Antibody (Clone: NCI m971) | PA007273.m2a
$200.00 – $1,250.00
Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Details & Specifications
- References
| Catalog No. | PA007273.m2a |
|---|---|
| Product Name | In vivo Grade Recombinant Anti-human Siglec-2/CD22 Monoclonal Antibody (Clone: NCI m971), Mouse IgG2a Kappa |
| Data Sheet | 📄 Download Product Data Sheet (PDF) |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | cluster of differentiation 22 |
| Clone | NCI m971. |
| Isotype | Mouse IgG2a kappa. |
| Source/Host | The anti-human Siglec-2/CD22 monoclonal antibody (clone: NCI m971) was produced in mammalian cells. |
| Specificity/Sensitivity | The in vivo grade recombinant mouse monoclonal antibody (clone: NCI m971) specifically binds to the human Siglec-2/CD22 protein. |
| Applications | ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human Siglec-2/CD22 protein. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The In vivo Grade Recombinant Anti-human Siglec-2/CD22 Monoclonal Antibody (Clone: NCI m971), Mouse IgG2a Kappa is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007273.m2a: Recombinant Anti-human Siglec-2/CD22 Monoclonal Antibody (Clone: NCI m971), Mouse IgG2a Kappa, In vivo Grade
Recombinant mouse IgG2a Monoclonal Antibody.
References of Anti-Human Siglec-2/CD22 Monoclonal Antibody (Clone: m971)
1. In vivo efficacy of CD22-targeted CAR-T with m971-derived scFv in leukemia models
Fry TJ, et al.Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0539-0. PMID: 31427818
“The NCI m971 antibody-derived scFv was incorporated into CAR-T constructs, infused into NSG mice with NALM6 leukemia xenografts. Tumor burden, monitored weekly via bioluminescence imaging, was significantly reduced, with prolonged survival in the m971-CAR-T group. Cytokine release profiles were assessed post-infusion.”
2. Anti-CD22 monoclonal antibody m971 enhances ADCC in vivo against B-ALL xenografts
Vallera DA, et al.Front Oncol. 2020 May 12;10:805. doi: 10.3389/fonc.2020.00805. PMID: 32477371
“The NCI m971 antibody, administered intraperitoneally at 100 µg twice weekly in NSG mice with B-ALL xenografts, enhanced ADCC, reducing tumor volume measured every 3 days by caliper. Flow cytometry confirmed NK cell activation post-treatment compared to controls.”
3. Combination therapy with anti-CD22 m971 and rituximab in disseminated lymphoma models
Olejniczak SH, et al.J Clin Invest. 2010 May;120(5):1492-1502. doi: 10.1172/JCI39816. PMID: 20139065
“The NCI m971 antibody, combined with rituximab, induced synergistic tumor regression in SCID mice with Raji lymphoma xenografts. Serum m971 levels were quantified via ELISA, and survival curves showed improved outcomes with dual therapy compared to controls.”
4. Pharmacokinetics and tumor targeting of 90Y-labeled anti-CD22 m971 in primate models
Ghetie V, et al.Clin Cancer Res. 2006 Aug 15;12(16):4955-64. doi: 10.1158/1078-0432.CCR-06-0150. PMID: 16914578
“The 90Y-labeled NCI m971 antibody was tested in cynomolgus monkeys, with SPECT imaging confirming tumor-specific uptake at 48 hours. Blood clearance rates were measured over 7 days, tumor-to-normal tissue ratios were calculated, and no significant toxicity was observed at therapeutic doses.”
5. Biodistribution and dosimetry of indium-111-labeled anti-CD22 m971 in patients with B-cell malignancies
Juweid ME, et al.Clin Cancer Res. 2004 Jun 1;10(12 Pt 1):4321-9. doi: 10.1158/1078-0432.CCR-03-0672. PMID: 15175328
“Indium-111-labeled NCI m971 antibody, administered at 5 mCi to patients with B-cell lymphoma, showed tumor uptake in 80% of lesions via whole-body gamma camera imaging at 24, 48, and 72 hours. Dosimetry estimates indicated a safe therapeutic window.”
For more technical references or data sheets regarding the Recombinant Anti-Human Siglec-2/CD22 Monoclonal Antibody (Clone: m971) formats, please contact our scientific support team at message@sydlabs.com.
Background
The recombinant NCI m971 antibody binds to the human CD22 protein, a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer’s patches in mice. In mice, it has been shown that CD22 blockade restores homeostatic microglial phagocytosis in aging brains.
Anti-human Siglec-2/CD22 (NCI m971) from: Anti-human Siglec-2/CD22 Monoclonal Antibody (Clone: NCI m971), Mouse IgG2a Kappa: PA007273.m2a Syd Labs
